How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma

SIMPLE SUMMARY: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were drugs originally intended for the management of diabetes, while their role on the treatment of nonalcoholic steatohepatitis (NASH), and NASH-related hepatocellular carcinoma (HCC), has been at the forefront of medical investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Arvanitakis, Konstantinos, Koufakis, Theocharis, Kotsa, Kalliopi, Germanidis, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562923/
https://www.ncbi.nlm.nih.gov/pubmed/36230573
http://dx.doi.org/10.3390/cancers14194651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562923/
https://www.ncbi.nlm.nih.gov/pubmed/36230573
http://dx.doi.org/10.3390/cancers14194651

Ejemplares similares